U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.You may also be interested in...
GSK Retrovir Goes Generic
Zidovudine ANDAs from Ranbaxy, Roxane and Aurobindo are the first generic pediatric AIDS drugs approved for the U.S. market.
GSK Retrovir Goes Generic
Zidovudine ANDAs from Ranbaxy, Roxane and Aurobindo are the first generic pediatric AIDS drugs approved for the U.S. market.
Ranbaxy Files Three Antiretroviral ANDAs Under Expedited Review Process
The generic firm's versions of zidovudine, lamivudine and nevirapine were filed under the President's Emergency Plan for AIDS Relief. The products will only be sold in the developing world; Ranbaxy plans to file a total of 15 ANDAs under the plan by the second quarter.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: